Medpace (NASDAQ:MEDP) Shares Down 3.7% After Insider Selling

Medpace Holdings, Inc. (NASDAQ:MEDP)’s stock price was down 3.7% during mid-day trading on Thursday following insider selling activity. The company traded as low as $530.96 and last traded at $554.93. Approximately 157,218 shares were traded during trading, a decline of 61% from the average daily volume of 408,083 shares. The stock had previously closed at $576.49.

Specifically, CEO August J. Troendle sold 23,178 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $593.25, for a total value of $13,750,348.50. Following the sale, the chief executive officer directly owned 652,550 shares of the company’s stock, valued at approximately $387,125,287.50. This trade represents a 3.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO August J. Troendle sold 15,151 shares of the company’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $593.46, for a total transaction of $8,991,512.46. Following the transaction, the chief executive officer directly owned 675,728 shares of the company’s stock, valued at approximately $401,017,538.88. This represents a 2.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In other news, CEO August J. Troendle sold 41,331 shares of the stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $606.88, for a total transaction of $25,082,957.28. Following the transaction, the chief executive officer directly owned 690,879 shares in the company, valued at $419,280,647.52. This represents a 5.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Truist Financial set a $555.00 price target on shares of Medpace in a research report on Monday, October 27th. BMO Capital Markets assumed coverage on shares of Medpace in a research note on Thursday, November 13th. They set a “market perform” rating and a $600.00 price objective for the company. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medpace in a research report on Friday, October 31st. Jefferies Financial Group lifted their target price on Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a report on Tuesday, September 9th. Finally, Robert W. Baird set a $613.00 price target on Medpace in a research note on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have issued a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat.com, Medpace presently has an average rating of “Hold” and an average price target of $487.18.

Medpace Stock Down 3.7%

The firm’s 50 day moving average price is $565.74 and its two-hundred day moving average price is $450.35. The firm has a market capitalization of $15.63 billion, a PE ratio of 38.81, a P/E/G ratio of 2.21 and a beta of 1.43.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. During the same quarter in the previous year, the firm posted $3.01 EPS. The firm’s quarterly revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Institutional Trading of Medpace

Hedge funds and other institutional investors have recently modified their holdings of the business. Quent Capital LLC purchased a new position in Medpace in the third quarter valued at about $25,000. Optiver Holding B.V. purchased a new stake in Medpace during the 3rd quarter worth approximately $27,000. Geneos Wealth Management Inc. increased its holdings in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Brooklyn Investment Group raised its position in shares of Medpace by 244.8% in the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock valued at $30,000 after purchasing an additional 71 shares in the last quarter. Finally, Quarry LP purchased a new position in shares of Medpace during the 3rd quarter valued at approximately $35,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.